YS5
Based on 1 Customer Validation
YS5 (FOR 46/FG-3246 antibody) is an anti-CD46 antibody. YS5 can serve as an ADC Antibody to synthesize the ADC FOR 46/FG-3246. YS5 is applicable to research related to metastatic castration-resistant prostate cancer.
For research use only. We do not sell to patients.
- Purity: 98.01%
- Molecular Weight:145.5 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
CD46
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
P15529-1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of Hela cells labelling CD46 (red) with YS5 (HY-P990586). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Immobilized CD46 Protein, Human can bind YS5. The EC50 for this effect is 7.35 ng/mL.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 145.5 kDa
-
Color Colorless to light yellow
-
Synonyms
FOR 46/FG-3246 antibody
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Aggarwal RR, et al. Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025 May 20;43(15):1824-1834. [Content Brief]
[2]. Ozay ZI, et al. Antibody-drug conjugates in prostate cancer: current landscape and future directions. Therapeutic advances in medical oncology. 2026;18:17588359261424672. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)